salicylsalicylic acid has been researched along with Cardiometabolic Syndrome in 3 studies
salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Salsalate regulated inflammation by affecting the expression of genes from MAPK signalling and NOD-like receptor signalling pathways and lipid metabolism by affecting hepatic expression of genes that favour lipid oxidation from PPAR-α signalling pathways." | 1.46 | Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls. ( Haluzík, M; Kazdová, L; Kuda, O; Landa, V; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Strnad, H; Trnovská, J; Zídek, V, 2017) |
| " Salicylate, unlike aspirin, is only a very weak, reversible inhibitor of cyclooxygenase in clinical doses, and thus is not associated with the potentially dangerous side effects seen with NSAIDs; fully reversible ototoxicity, the dose-limiting side effect in salicylate therapy, can be avoided in most patients by dosage adjustment." | 1.36 | Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. ( McCarty, MF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trnovská, J | 1 |
| Šilhavý, J | 1 |
| Kuda, O | 1 |
| Landa, V | 1 |
| Zídek, V | 1 |
| Mlejnek, P | 1 |
| Šimáková, M | 1 |
| Strnad, H | 1 |
| Škop, V | 1 |
| Oliyarnyk, O | 1 |
| Kazdová, L | 1 |
| Haluzík, M | 1 |
| Pravenec, M | 1 |
| Nohria, A | 1 |
| Kinlay, S | 1 |
| Buck, JS | 1 |
| Redline, W | 1 |
| Copeland-Halperin, R | 1 |
| Kim, S | 1 |
| Beckman, JA | 1 |
| McCarty, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inflammation and Vascular Function in Atherosclerosis[NCT00760019] | Phase 2/Phase 3 | 58 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865] | Phase 2 | 59 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow-mediated, endothelium-dependent vasodilation (percentage increase in brachial artery diameter after a 5 minute ischemic stimulus) measured at the end of placebo treatment and end of salsalate treatment were compared. (NCT00760019)
Timeframe: Upon completion of 4 weeks of salsalate and placebo treatment
| Intervention | percentage vasodilation (Median) |
|---|---|
| Salsalate | 6.8 |
| Placebo | 8.7 |
Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks
| Intervention | Percent dilation (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| Placebo | 3.57 | 2.50 |
| Salsalate | 3.49 | 4.60 |
| Young Control Group | 5.88 | NA |
Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks
| Intervention | cm/sec (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| Placebo | 785.1 | 740.01 |
| Salsalate | 831.3 | 839.6 |
| Young Control Group | 538.0 | NA |
1 trial available for salicylsalicylic acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
The effect of salsalate therapy on endothelial function in a broad range of subjects.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biomarkers; Boston; Cross-Ove | 2014 |
2 other studies available for salicylsalicylic acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls.
Topics: Adipose Tissue, Brown; Animals; Animals, Genetically Modified; C-Reactive Protein; Fatty Acids, None | 2017 |
Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome.
Topics: Dose-Response Relationship, Drug; Humans; I-kappa B Kinase; Metabolic Syndrome; NF-kappa B; Oxidativ | 2010 |